Bluesight today announced Medicare Revenue Optimizer within its popular CostCheck platform to support hospital pharmacies. This, therefore, means that healthcare organizations can compare the reimbursement of medications against the procurement costs for drugs. Moreover, this improvement makes it easy for the procurement manager to recognize profitable drug procurement alternatives.
Bluesight also unveiled Claims-Based Revenue Optimizer as early access in late 2026. Together, these features assess payer-level reimbursement data for maximum financial growth. This combination helps ensure that the procurement specialist maximizes all opportunities through the procurement process.
At present, more than 500 facilities in the United States use CostCheck to procure their daily drugs. The software analyzes complicated contracts, invoices, and drugs to eliminate unnecessary spending effectively. Moreover, it identifies cost-saving NDCs along with billing errors.
Historically, the software has helped hospital pharmacies capture savings between 1% and 9% annually.
Unlocking Revenue Intelligence Beyond Basic Savings
With Medicare Revenue Optimizer, Bluesight adds a strategic intelligence layer directly into procurement workflows. Specifically, the platform embeds Medicare Part B reimbursement data into Recommended Changes workflows seamlessly. This automated system empowers pharmacy staff to evaluate pricing trends without extra administrative overhead.
As a result, staff view estimated cost impact and margin impact side by side. Procurement teams at hospital pharmacies can instantly choose medications that offer lower costs and higher reimbursements.
Later this year, Bluesight will launch Claims-Based Revenue Optimizer for customized data integration. Consequently, health systems can connect proprietary claims data to evaluate unique payer mixes.
This integration helps hospital pharmacies move beyond public estimates toward precise financial forecasting. Thus, leaders gain actionable financial context for every single purchasing decision they execute. Consequently, organizations protect their operational budgets against market volatility.
Navigating Changing Healthcare Economic Environment and Policy Trends
The present product development is introduced amid rising projections for outpatient care up to 18% during the coming ten years. Nevertheless, projections for inpatient care will stay modest at 5%.
Nonetheless, implementation of site-neutral payment policies will result in lowering outpatient drug administration costs by $290 million in 2026. In addition, proposed 2027 OPPS regulations may result in almost a 40% reduction in 340B drug reimbursements. Hence, the above-mentioned changes put pressure on hospital pharmacies dealing with specialty products.
With regard to specialty and biosimilar drugs, traditionally the purchasers had no idea about their revenue potential. The team from Bluesight found that interchangeably biosimilar drug revenue fluctuations per vial are $550 losses and $1,500 gains. Thus, the decision-making based only on acquisition costs will lead to a negative impact on total hospital margin.
Revenue Insights Integration Transforms Pharmacy Into a Profit Center
Moreover, the implementation of revenue insights in the drug purchasing process creates a solid basis for future expansion. Hospital Pharmacies will be able to align their clinical objectives with general company financial aims. Therefore, the new product allows optimizing pharmacy purchasing decisions for maximum profitability.
“For years, hospital pharmacy has lived in the ledger as a cost center,” said Kevin MacDonald, CEO and Co-Founder of Bluesight. “CostCheck is leading a shift toward pharmacy as a revenue generator. Pharmacy teams can now see, at the moment of decision, whether a purchase saves money up front, earns more when billed, or both. As a result, health system leadership gets a single, credible number for pharmacy’s full financial contribution.”
Ultimately, Bluesight reinforces its market position as a primary intelligence provider for modern health systems. By integrating reimbursement analytics directly into daily workflows, the company drives sustainable financial health across the industry.
Looking for more updates on financial innovation and revenue-driven technology? Visit RevTech News for expert insights and the latest trends.
News Source: GlobeNewswire.com
